Clinical Trials Logo

Filter by:
NCT ID: NCT04815135 Completed - Emergencies Clinical Trials

Effect of Covid-19 Pandemic on Emergency Surgery Practice

Start date: March 1, 2019
Phase:
Study type: Observational

A retrospective study at a tertiary university hospital to determine the effect of the COVID-19 pandemic on the emergency surgery practice in the hospital.

NCT ID: NCT04812925 Active, not recruiting - Clinical trials for Primary Immune Thrombocytopenia

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

ADVANCE SC+
Start date: November 17, 2021
Phase: Phase 3
Study type: Interventional

A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia

NCT ID: NCT04810000 Completed - Clinical trials for Arthroplasty Complications

The Effect of Releasing the Tourniquet in Total Knee Replacement Before Closure on the Blood Loss , Joint Effusion , Hematoma Formation and Wound Complication

Start date: December 3, 2018
Phase:
Study type: Observational [Patient Registry]

The study , observe the effect of releasing the Tourniquet in total knee replacement surgery before closure in comparison with releasing it after wound closure The effect was assessed by Hb drop post operative and Hematoma formation ( measured by ultrasound ) as well as the wound complication

NCT ID: NCT04780464 Terminated - Clinical trials for Advanced Soft-tissue Sarcoma

A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma

Tolerance
Start date: April 11, 2022
Phase: Phase 3
Study type: Interventional

This is a multi-centre, open label, randomized phase 3 selection study (1:2:2 randomization). After confirmation of the eligibility criteria, 185 patients will be randomized 1:2:2 to either the control arm (doxorubicin 60-75 mg/m² IV every 3 weeks) or experimental arm 1 (doxorubicin 12 mg/m2 IV every week) or experimental arm 2 (cyclophosphamide 100 mg orally BD plus prednisolone 10-20 mg orally on day 1 to day 7 of each 14 day cycle). HRQoL assessment will be performed every 3 weeks during the first 12 weeks and every 12 weeks thereafter until month 12 after start of treatment. Disease evaluation will be performed every 12 weeks until progression. The primary endpoint of the study is difference among the study arms in physical and role functioning at 12 weeks.

NCT ID: NCT04779528 Completed - Anesthesia Clinical Trials

Awake Nasal Fiber-optic Intubation of Severely Obese Patients in Lateral Position

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Airway management in severely obese patients remains a challenging issue for anesthetists and may lead to life-threatening situations. Awake Fiber-Optic Bronchoscopy Intubation (FOBI) technique is considered as the gold standard when a difficult airway is anticipated to secure the airway and to facilitate the surgery. FOBI is usually done in supine position, while (in conscious patients) lateral position is the most recommended position to keep the upper airway patent. This prospective clinical trial study will test whether awake FOBI in Lateral position will provide a safe profile or a significant advantage over FOBI in supine position, in morbidly obese patients undergoing elective bariatric surgery.

NCT ID: NCT04779515 Completed - Pain Clinical Trials

Effect of Low-pressure Pneumoperitoneum on Pain and Inflammation Post Laparoscopic Cholecystectomy

Start date: January 20, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effect of low-pressure pneumoperitoneum on post operative pain and inflammation in patients undergoing elective laparoscopic cholecystectomy by comparing it to standard practice.

NCT ID: NCT04759638 Completed - Rectal Cancer Clinical Trials

Short Running Head Obesity in Rectal Cancer Patients

Start date: March 21, 2017
Phase:
Study type: Observational

There is a controversy regarding the effect of the two Body Mass Index (BMI) extremes on the oncological outcome of rectal cancer. The obesity paradox appears to exist in rectal cancer patients treated with nCRT and surgery, as it was associated with significantly higher rates of pathological complete response and R0 resection. Underweight patients were at higher risk for anastomotic leak and R1 resection.

NCT ID: NCT04756102 Completed - Maternal Diabetes Clinical Trials

Glucose Levels in Early Pregnancy and Feto-maternal Outcome

Start date: January 30, 2018
Phase:
Study type: Observational

to find out whether variations in the fasting blood glucose in early pregnancy affect the fetomaternal outcome

NCT ID: NCT04747184 Completed - Asthma Clinical Trials

Variations in the Composition of Respiratory Microbiota

Start date: December 1, 2019
Phase:
Study type: Observational

Induced sputum samples were obtained from 27 asthmatic patients and 27 non-asthmatic subjects. Sequencing of the V4 region of 16S rRNA gene using Illumina MiSeq was performed, followed by analysis of alpha and beta diversity.

NCT ID: NCT04731051 Withdrawn - Clinical trials for 2019 Novel Coronavirus

The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients

Start date: October 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pilot, randomized, single-center, parallel group, open-label controlled study to evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus Standard of Care (SOC) versus SOC alone in hospitalized cancer patients with COVID-19. King Hussein Cancer Center (KHCC) is the study sponsor, and the study will be conducted at KHCC COVID-19 wards. Approximately 28 cancer patients, ≥18 years of age with a confirmed SARS-CoV-2 infection, will be enrolled and randomized 1:1 to the treatment and control arms where they will receive ten doses of Hydroxychloroquine solution via nebulizer in addition to SOC or the control arm where treatment will follow KHCC SOC.